CG Oncology CGON
United StatesHealthcare · BiotechnologyUSD
91.08 USD (+46.0%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
CG Oncology is a clinical-stage biopharmaceutical company focused on developing oncology therapies, primarily for bladder cancer, with a business model based on research and development of drug candidates that do not yet generate product revenues.
Key points
from its scores- ✓Good share-price trend9.2
- ✓Favourable backdrop8.4
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.7
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHold only for investors with high risk tolerance and a long-term horizon, as the current valuation discounts a clinical success that is not yet confirmed.
CG Oncology is a pre-revenue biotech with a very solid cash position (liquidity 22.22) but an operating margin of -7467.68% and an ROIC of -44.64%, reflecting its development stage. The strong stock momentum (67.28% over 12 months) contrasts with the lack of growth and valuation data, making its score depend almost entirely on the clinical and regulatory progress of its lead candidate.
The main risk is the clinical or regulatory failure of its lead oncology candidate, which would leave the valuation without fundamental support as the company has no revenues or approved products.
Context and risks
CG Oncology is a development-stage biotech with no product revenues, a deeply negative operating margin and an ROIC of -44.64%. Its valuation depends on the regulatory approval of its lead oncology candidate, an inherent business model risk of the sector that no financial metric captures. The governance risk of the country of domicile (United States) is moderate, adding a small additional penalty.
Is CG Oncology stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 5.4 | 4.1 | +30% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 91.08 USD, +46.0% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −20.7
- EV / EBITDA
- −18.1
- Price / book
- 5.4
- Price / sales
- 887.8
- Market cap
- 5.5B USD
- Enterprise value
- 4.5B USD
Profitability
- ROE
- −26.4%
- ROA
- −17.7%
- ROIC (approx.)
- −44.6%
- Gross margin
- 0.0%
- Operating margin
- −7,467.7%
- Net margin
- 0.0%
- Free cash flow
- −113.7M USD
- FCF yield
- −2.1%
Solvency
- Total debt
- 8.8M USD
- Net debt
- −1.0B USD
- Cash
- 1.0B USD
- EBITDA
- −249.7M USD
- Net debt / EBITDA
- 4.08
- Debt / equity
- 0.86
- Current ratio
- 22.22
- Quick ratio
- 21.78
Growth
- EPS (TTM)
- −2.69 USD
- EPS (forward)
- −3.02 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.28
- Analyst consensus
- none (13)
- Target price
- 91.08 USD
- 52-week range
- 35.80 – 80.97
Recent news
All CGON news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about CG Oncology
Is CG Oncology stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 91.08 USD, +46.0% versus the price. This is not investment advice.
What score does CG Oncology get on MeridIAn Screener?
It scores 3.2 out of 10, rank 2,054 of 2,130 (better than 3% of the companies analysed). Its strongest category is Momentum (9.2) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is CG Oncology worth on the stock market?
Its market capitalisation is 5.5B USD and its enterprise value, debt included, is 4.5B USD.
How much debt does CG Oncology have?
It has more cash than debt: net cash of 1.0B USD.
Does CG Oncology pay a dividend?
It pays no dividend, or almost none.
How has CG Oncology stock performed over the last year?
It has risen 44.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 35.80 and 80.97 USD. Past performance does not guarantee future results.
What do analysts think of CG Oncology?
13 analysts cover it; their average recommendation is “none” and their average target is 91.08 USD (+46.0% versus the price). It is an estimate, not market data.